
Unlocking the Potential of AXS-12: A Promising Treatment for Narcolepsy – A Closer Look at Axsome’s Latest Positive Data Release
Axsome’s AXS-12 Phase 3 Study Shows Promising Results for Narcolepsy Patients Introduction Axsome Therapeutics recently announced that its drug AXS-12 has met its primary endpoint in a Phase 3 study, showing significant reduction in cataplexy attacks in narcolepsy patients. This achievement positions AXS-12 for a potential New Drug Application (NDA) submission in the near future….